About Us

RJH Biosciences is a start-up company that focuses on realizing the full potential of nucleic acids for human health by developing vehicles to effectively deliver nucleic acids.

We develop novel transfection agents that deliver different types of nucleic acids to a range of human cells in culture, while tailoring the transfection agents further to act as delivery vehicles for clinical therapy involving nucleic acids.
The company was established in 2016 based on long history of technical expertise developed at the University of Alberta (Edmonton, Alberta, Canada).

The company intends to develop value-added products in three commercial segments, as transfection reagents for biomedical R&D enterprise, as transfection reagents in biomanufacturing industry and as nucleic acid delivery agents for clinical applications.

Core Values


We design and develop unique materials for effective delivery of nucleic acids to meet the emerging needs in biomedical enterprise. Accomplishing the task at hand is what drives our venture.


We are dedicated to understanding the performance of our products in the hands of our customers to reveal the scientific basis of their actions. Establishing such a foundation will guide our efforts to overcome future challanges

Collaboration & Personal Development

We work closely with our customers, fellow researcher and scientists to realize shared scientific and technical aspirations. We create a supportive environment to foster entrepreneurial spirit of our team members and collaborators.


We deliver a value-added product that overcomes impediments in everyday practice. We enable our product users to go further, to see beyond and overcome impediments that has not been possible before.


Dr. Hasan Uludağ

Dr. Uludağ is currently serving as the President of RJH Biosciences. He is a Professor of Engineering at the University of Alberta. Dr. Uludağ directs interdisciplinary research programs on experimental therapeutics, specifically designing functional biomaterials to realize the potential of unconventional therapeutic agents based on nucleic acids.

Dr. Uludağ is actively involved in various biomaterials societies around the World and is an elected Fellow of the International Union of Society of Biomaterials Science and Engineering (IUS-BSE). Dr. Uludağ published >160 peer-reviewed journal articles. Dr. Uludağ obtained dual B.Sc. degrees in Biomedical Engineering and Biology from Brown University (Providence, RI, USA) in 1989, specializing in biomedical engineering and biological sciences. He then completed his Ph.D. degree in 1993 at the Department of Chemical Engineering & Applied Chemistry at the University of Toronto (Toronto, Canada), where he developed a strong expertise in polymeric biomaterials. He spent four years at a pharmaceutical company (Genetics Institute Inc.; Boston, MA, USA) and contributed to development of a tissue engineered device for clinical use.

Dr. Remant KC

Dr. KC is a founding member and Director of Materials Development at RJH Bioscience. He has been working as a researcher at the University of Alberta, Department of Chemical & Material Engineering. He received his M.Sc. degree in organic chemistry from the Tribhuvan University (Nepal) and Ph.D. in Bionanosystem Engineering from the Chonbuk National University (South Korea).

Dr. KC has been working in interdisciplinary research projects at the interface of science, engineering and biology for the last 15 years as a principal investigator and co-investigator. His research expertise spans polymer chemistry, engineering of nanoparticulate systems, and gene/drug therapy for cancer. He is the inventor on 6 international patents and authored >45 peer reviewed publications.

Dr. Juliana Valencia-Serna

Dr. Valencia is a founding member and Director of Therapeutic Development at RJH Biosciences. She received her undergraduate degree in Biomedical Engineering from the Antioquia´s School of Engineering and CES University (Colombia). Dr. Valencia has been a visiting scientist at the El-Sayed Lab, the University of Michigan (USA) and collaborated in a project involving delivery of nanoparticles to vitro tumors models. She worked as a researcher at the CES University and constructed scaffolds for tissue engineering applications.

Dr. Valencia subsequently joined the Uludag lab in 2011 as a PhD student in Biomedical Engineering, where she investigated the use of novel biomaterials for therapeutic siRNA delivery in leukemia models. Dr. Valencia led a local biomaterials group and organized several events that allowed the interaction of biotech company leaders with students looking for careers outside of academia.